# A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

> **NCT01565707** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 189 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Solifenacin Succinate Suspension
- **DRUG:** Placebo
- **BEHAVIORAL:** Urotherapy

## Key facts

- **NCT ID:** NCT01565707
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-07
- **Primary completion:** 2013-12-31
- **Final completion:** 2014-01-02
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01565707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01565707, "A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01565707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*